1. Patients aged â?¥18 and â?¤60 years and voluntarily willing to provide signed and dated informed consent. <br/ >2. Patients with laboratory confirmed COVID-19 by SARS CoV2 positive RT-PCR test (within 48 hours prior to enrollment) <br/ >3. Patients with mild COVID-19 disease without any evidence of breathlessness. <br/ >4. 4. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment serum or urine pregnancy test and agree to take effective contraceptive measures (barrier methods or abstinence) with his/her partner during the study period and for at least 28 days following the last study treatment.

1. Patients aged â?¥18 and â?¤60 years and voluntarily willing to provide signed and dated informed consent. <br/ >2. Patients with laboratory confirmed COVID-19 by SARS CoV2 positive RT-PCR test (within 48 hours prior to enrollment) <br/ >3. Patients with mild COVID-19 disease without any evidence of breathlessness. <br/ >4. 4. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment serum or urine pregnancy test and agree to take effective contraceptive measures (barrier methods or abstinence) with his/her partner during the study period and for at least 28 days following the last study treatment.

1. Patients aged â?¥18 and â?¤60 years and voluntarily willing to provide signed and dated informed consent. <br/ >2. Patients with laboratory confirmed COVID-19 by SARS CoV2 positive RT-PCR test (within 48 hours prior to enrollment) <br/ >3. Patients with mild COVID-19 disease without any evidence of breathlessness. <br/ >4. 4. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment serum or urine pregnancy test and agree to take effective contraceptive measures (barrier methods or abstinence) with his/her partner during the study period and for at least 28 days following the last study treatment.

1. Patients aged â?¥18 and â?¤60 years and voluntarily willing to provide signed and dated informed consent. <br/ >2. Patients with laboratory confirmed COVID-19 by SARS CoV2 positive RT-PCR test (within 48 hours prior to enrollment) <br/ >3. Patients with mild COVID-19 disease without any evidence of breathlessness. <br/ >4. 4. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment serum or urine pregnancy test and agree to take effective contraceptive measures (barrier methods or abstinence) with his/her partner during the study period and for at least 28 days following the last study treatment.